Entering text into the input field will update the search result below

Merck KGaA nabs CRISPR patent in Australia

Aug. 15, 2018 8:54 AM ETMerck KGaA (MKGAF) StockMKGAY, MKGAF, EDIT, NTLA, CRSPBy: Douglas W. House, SA News Editor3 Comments
  • The Australian Patent Office awards a patent to Merck KGaA (OTCPK:MKGAF)(OTCPK:MKGAY) covering the use of paired CRISPR nickases, an approach aimed at reducing off-target effects during gene editing.
  • CEO, Life Science business of Merck KGaA Udit Batra says, “We’ve made tremendous strides in recent years evolving CRISPR technology, and this is a pivotal time in scientific research. Our paired nickase CRISPR technology is important for researchers who need highly accurate methods when developing treatments for difficult-to-treat diseases. This new patent allowance represents a significant advancement in safety for CRISPR-enabled therapeutics.”
  • Related tickers: (NASDAQ:CRSP)(NASDAQ:EDIT)(NASDAQ:NTLA)

Recommended For You

About MKGAF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MKGAF--
Merck KGaA